APOE2 Heterozygosity Reduces Hippocampal Soluble Amyloid-β42 Levels in Non-Hyperlipidemic Mice
Journal of Alzheimer’s Disease · 2024
DOI: 10.3233/jad-231210 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Ana C Valencia-Olvera und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Apolipoprotein E2, Hippocampus. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
APOE2 lowers Alzheimer’s disease (AD) risk; unfortunately, the mechanism remains poorly understood and the use of mice models is problematic as APOE2 homozygosity is associated with hyperlipidemia. In this study, we developed mice that are heterozygous for APOE2 and APOE3 or APOE4 and overexpress amyloid-β peptide (Aβ) (EFAD) to evaluate the effect of APOE2 dosage on Aβ pathology. We found that heterozygous mice do not exhibit hyperlipidemia. Hippocampal but not cortical levels of soluble Aβ 42 followed the order E2/2FAD > E2/3FAD≤E3/3FAD and E2/2FAD > E2/4FAD < E4/4FAD without an effect on insoluble Aβ 42 . These findings offer initial insights on the impact of APOE2 on Aβ pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, USA.
- University of Illinois College of Medicine, IL, USA.
- University of Miami/Jackson Healthcare System, Miami, FL, USA.
- Alzheimer Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Research and Development Service, James J. Peters VA Medical Center, Bronx, NY, USA.
- Department of Neurology, N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN, USA.
Förderung
- NIA NIH HHS
Zitieren
APA
Valencia-Olvera, A. C., Balu, D., Moore, A., Shah, M., Ainis, R., Xiang, B., Saleh, Y., Cai, D., LaDu, M. J., & Tai, L. M. (2024). APOE2 Heterozygosity Reduces Hippocampal Soluble Amyloid-β42 Levels in Non-Hyperlipidemic Mice. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-231210
Vancouver
Valencia-Olvera AC, Balu D, Moore A, Shah M, Ainis R, Xiang B, et al. APOE2 Heterozygosity Reduces Hippocampal Soluble Amyloid-β42 Levels in Non-Hyperlipidemic Mice. Journal of Alzheimer’s Disease. 2024. doi:10.3233/jad-231210
BibTeX
@article{ValenciaOlvera2024,
author = {Valencia-Olvera, Ana C and Balu, Deebika and Moore, Annabelle and Shah, Maitri and Ainis, Rebecca and Xiang, Bingtao and Saleh, Yaseen and Cai, Dongming and LaDu, Mary Jo and Tai, Leon M},
title = {APOE2 Heterozygosity Reduces Hippocampal Soluble Amyloid-β42 Levels in Non-Hyperlipidemic Mice},
journal = {Journal of Alzheimer’s Disease},
year = {2024},
doi = {10.3233/jad-231210}
}
EUVIMED